Group 1: Kao Corporation - Kao Corporation participated in the 8th China International Import Expo with the theme "Co-creating Beauty, Quality for the Future," showcasing its global innovation and local integration achievements [3] - The company presented a range of products tailored for the Chinese market, including upgraded cleansing oils and sunscreen solutions, emphasizing its commitment to high-quality living for Chinese consumers [4] Group 2: Nippon Paint and GAC Aion - Nippon Paint and GAC Aion announced a strategic partnership during the expo, focusing on the development of coatings for flying cars and lightweight material protection, aiming to enhance the quality of China's low-altitude economy [6] - GAC Aion's AirCab is in the civil aviation certification phase, with plans for mass production in late 2026 and manned flights in 2027, while Nippon Paint introduced a comprehensive coating solution for low-altitude flying vehicles [6] Group 3: LEGO Group - LEGO Group showcased an immersive "City of Play" at the expo, featuring eight themed areas and a model of Shanghai made from nearly 100,000 bricks, promoting cultural connection and sustainability [8][10] - The company hosted multiple activities during the event, including global product launches and sustainability discussions, reinforcing its commitment to engaging with Chinese consumers [8] Group 4: Bayer - Bayer launched the "Allergy Star Survival Guide" during the expo, focusing on the prevention and treatment of allergic diseases, which affect nearly 250 million people in China [11] - The initiative aims to shift from passive treatment to proactive management of allergies, emphasizing the importance of early intervention and appropriate medication [11] Group 5: Herbalife - Herbalife introduced its MultiBurn supplement at the expo, targeting weight management through a blend of plant extracts that support metabolism and fat reduction [14] - The company highlighted the importance of a scientific approach to weight management, aligning with consumer demands for effective and sustainable health solutions [14]

Core Insights - The eighth China International Import Expo (CIIE) showcased 461 new products, technologies, and services, establishing itself as a platform for global innovation and market entry [2] - Major global companies in the medical device and healthcare sectors, including Johnson & Johnson, Roche, and Pfizer, participated, highlighting the expo's role in promoting high-end medical equipment and innovative pharmaceuticals [2][3] - The expo has accelerated the registration and market entry processes for new medical products, exemplified by Medtronic's Micra product, which achieved rapid commercialization following its global debut at the first CIIE [3] Medical Devices and Healthcare - The expo featured significant innovations such as Johnson & Johnson's ETHICON 4000 3D stapler and Siemens Healthineers' ARTIS icono ceiling Xpand, indicating a shift in China's high-end medical device sector from "catching up" to "leading" [2] - Medtronic's focus on AI integration in healthcare was evident with the introduction of seven new products, showcasing the company's commitment to innovation in the medical field [2][3] - The integration of clinical practitioners and entrepreneurs is expected to foster more original innovations in the healthcare sector [2] Consumer Trends - The expo introduced new themes such as the silver economy, ice and snow economy, and sports economy, along with platforms for digital and health consumption, enhancing consumer experiences [3] - Companies like JoShan Health Technology showcased an AI-driven health management ecosystem, reflecting a trend towards personalized and intelligent home fitness solutions [4] Economic Impact - Panasonic highlighted its innovative products aimed at enhancing quality of life, emphasizing the dual focus on user scenarios and AI industry infrastructure development in China [5] - Shanghai has rapidly developed its first-launch economy, hosting over 2,000 first-launch events this year and seeing significant growth in e-commerce transactions, with a 12.7% year-on-year increase [5]

Financial Data and Key Metrics Changes - Herbalife reported Q3 net sales of $1.3 billion, up 2.7% year-over-year, marking the first quarter of net sales growth since Q1 2024 [5][20] - Adjusted EBITDA for Q3 was $163 million, exceeding guidance, with an adjusted EBITDA margin of 12.8%, down 60 basis points year-over-year [22][24] - The total leverage ratio was reduced to 2.8 times, outperforming the three-times commitment, with strong operating cash flows of $139 million, up 40% from Q3 2024 [24][20] Business Line Data and Key Metrics Changes - North America achieved its first quarterly growth since Q2 2021, with net sales up 1% year-over-year, driven by favorable pricing on flat volumes [27][21] - Latin America reported a solid quarter with net sales up 11% year-over-year, primarily due to favorable pricing impacts and improved sales mix [25] - EMEA net sales increased 4% on a reported basis, while Asia-Pacific remained relatively flat, indicating mixed performance across regions [26][28] Market Data and Key Metrics Changes - North America saw a significant sequential improvement in year-over-year net sales trend by approximately 480 basis points [27] - China experienced a decline in net sales by 5% year-over-year, primarily due to a 12% decline in volumes [28] - India reported a 4% increase in net sales on a reported basis, driven by favorable pricing and a 5% increase in volume [26] Company Strategy and Development Direction - Herbalife aims to be the world's premier health and wellness company, focusing on personalized nutrition and leveraging technology to enhance distributor engagement [4][9] - The company is introducing Protocol, a next-generation digital personalized health operating system, to deepen engagement and drive growth [6][8] - Linked Bioscience acquisition will enable Herbalife to deliver precision-made supplements tailored to individual needs, enhancing its competitive edge [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation, highlighting strong cash flow, reduced leverage, and targeted investments in innovation [17][35] - The company anticipates continued growth in net sales and adjusted EBITDA for Q4, with guidance reflecting currency volatility [31][33] - Management emphasized the importance of personalized nutrition and the role of distributors in driving business success [60][61] Other Important Information - Herbalife launched new products, including HL Skin and Baseline, showcasing its ability to innovate and respond to global health trends [15][17] - The company opened a new state-of-the-art R&D facility in Torrance, California, to enhance product development capabilities [12][14] - Engagement metrics from the Protocol beta group indicate strong distributor participation and enthusiasm for new technology [7][39] Q&A Session Summary Question: Capital allocation and debt reduction strategy - Management clarified that the focus remains on reducing debt while exploring opportunities for internal investments [36][37] Question: Costs associated with new product introductions - Management indicated that there would be no significant increase in SG&A costs related to distributor education on new products [38] Question: Early responses from the Protocol beta group - Feedback from the beta group has been positive, with high engagement levels and valuable insights for product development [39][40] Question: New distributor growth and productivity - The growth in new distributors is attributed to excitement about future products and ongoing engagement initiatives [42] Question: AI development for skincare products - The AI tool for skincare was developed in partnership and has shown impressive engagement metrics since launch [44] Question: Volume growth drivers and product mix - There is a slight shift towards healthy active lifestyle products, with a renewed focus on weight loss due to the launch of MultiBurn [45][47] Question: Expansion of the Mastermind program in India - The program has received positive feedback and is seen as essential for sustaining growth in the region [48][49] Question: Subscription revenue opportunities - Management believes subscription revenue will play a significant role in the future, with ongoing developments in this area [57][58]

Financial Performance - Q2 2025 net sales reached $1.3 billion, aligning closely with the midpoint of the company's guidance range[12] - Adjusted EBITDA for Q2 2025 was $174 million, surpassing the company's guidance[12] - The company repaid $55 million in debt, including $50 million of 2025 Notes[12] - The company's gross profit margin increased by 10 bps year-over-year to 78%[31] - Adjusted diluted EPS was $0.59, which includes an $0.11 year-over-year foreign exchange headwind[31] Regional Performance - New distributor growth occurred in 4 out of 5 regions year-over-year, with Latin America leading at a 16% increase[12] - Worldwide net sales decreased by 1.7% year-over-year, but remained flat on a constant currency basis[34] - Latin America experienced a 9% increase in local currency net sales[34] Product Launches and Initiatives - The company launched the Herbalife Flex45 Challenge globally[12] - The company expanded the Diamond Development Mastermind Program to South and Central America[12] - The company launched MultiBurn, a multifunctional weight-loss supplement[12] - The company unveiled the beta version of the Pro2col digital platform[12] Future Outlook - The company projects net sales to increase between 0.5% and 4.5% year-over-year for Q3 2025[42] - The company anticipates adjusted EBITDA between $150 million and $160 million for Q3 2025[42] - The company expects full-year 2025 net sales to range from a decrease of 1% to an increase of 3% year-over-year[42]